Table 3.
Drug-resistance characteristics of 84 CREL isolates.
| Isolate | MIC (μg/L) | Carbapenemase | ESBL | AmpC | OMPF | OMPC | ||
|---|---|---|---|---|---|---|---|---|
| IPM | MEM | ETP | ||||||
| ECL-ZY01 | 64 | 64 | 64 | NDM-1 | – | + | 0.19↓ | 1.56↑ |
| ECL-ZY02 | 64 | 64 | 64 | NDM-1 | SHV-12 | + | 0.07↓ | 0.13↓ |
| ECL-ZY03 | 1 | 1 | 4 | – | CTX-M; TEM-30 | + | 0.10↓ | 2.07↑ |
| ECL-ZY04 | 1 | 1 | 2 | – | CTX-M; TEM-30 | – | 0.13↓ | 1.34↑ |
| ECL-ZY05 | 1 | 1 | 4 | – | – | + | 0.02↓ | 0.02↓ |
| ECL-ZY06 | 8 | 8 | 64 | – | CTX-M; TEM-1; SHV-12 | – | 0.01↓ | 1.36↑ |
| ECL-ZY07 | 1 | 1 | 4 | – | CTX-M; TEM-30 | + | 0.28↓ | 0.58↓ |
| ECL-ZY08 | 256 | 256 | 256 | NDM-1 | CTX-M; TEM-1; SHV-12 | + | 0.26↓ | 0.66↓ |
| ECL-ZY09 | 128 | 128 | 128 | NDM-1 | CTX-M; TEM-30; SHV-12 | + | 0.31↓ | 3.31↑ |
| ECL-ZY10 | 2 | 2 | 4 | – | – | + | 0.01↓ | 0.01↓ |
| ECL-ZY11 | 32 | 32 | 128 | IMP-8 | – | + | 0.01↓ | 0.02↓ |
| ECL-ZY12 | 1 | 1 | 4 | – | – | + | 0.29↓ | 3.69↑ |
| ECL-ZY13 | 256 | 256 | 256 | NDM-1 | TEM-1; SHV-12 | + | 0.54↓ | 0.63↓ |
| ECL-ZY14 | 2 | 2 | 4 | – | SHV-12 | + | 0.01↓ | 0.82↓ |
| ECL-ZY15 | 1 | 1 | 2 | – | – | + | 0.28↓ | 0.74↓ |
| ECL-ZY16 | 2 | 2 | 8 | – | CTX-M | + | 0.01↓ | 0.21↓ |
| ECL-ZY17 | 2 | 2 | 2 | – | CTX-M; TEM-1 | + | 0.19↓ | 2.76↑ |
| ECL-ZY18 | 128 | 128 | 128 | IMP-4 | CTX-M; TEM-1 | + | 0.01↓ | 0.09↓ |
| ECL-ZY19 | 1 | 1 | 4 | – | – | + | 0.06↓ | 6.48↑ |
| ECL-ZY20 | 1 | 1 | 2 | – | – | + | 0.22↓ | 7.52↑ |
| ECL-ZY21 | 1 | 1 | 2 | – | – | + | 0.19↓ | 5.41↑ |
| ECL-ZY22 | 256 | 256 | 256 | KPC-2 | CTX-M; TEM-1; SHV-12 | + | 0.01↓ | 0.01↓ |
| ECL-ZY23 | 8 | 16 | 64 | VIM-4 | + | 0.01↓ | 2.70↑ | |
| ECL-ZY24 | 256 | 256 | 256 | NDM-1 | TEM-1; SHV-12 | + | 0.20↓ | 0.47↓ |
| ECL-ZY25 | 2 | 2 | 4 | – | CTX-M | + | 0.74↓ | 0.01↓ |
| ECL-NX01 | 128 | 128 | 128 | NDM-1 | – | + | 0.61↓ | 10.92↑ |
| ECL-NX02 | 64 | 64 | 32 | NDM-1 | CTX-M; TEM-1 | + | 0.38↓ | 36.36↑ |
| ECL-NX03 | 128 | 128 | 128 | NDM-1 | – | + | 0.23↓ | 11.28↑ |
| ECL-NX04 | 128 | 128 | 128 | NDM-1 | – | + | 0.32↓ | 13.81↑ |
| ECL-NX05 | 32 | 32 | 32 | IMP-26 | TEM-30; SHV-12 | + | 0.65↓ | 6.99↑ |
| ECL-NX06 | 256 | 256 | 256 | NDM-1 | CTX-M; TEM-30 | – | 0.12↓ | 7.07↑ |
| ECL-NX07 | 32 | 32 | 32 | IMP-26 | TEM-30; SHV-12 | + | 0.01↓ | 6.06↑ |
| ECL-NX08 | 256 | 256 | 256 | NDM-1 | CTX-M; TEM-30 | – | 0.09↓ | 0.01↓ |
| ECL-NX09 | 128 | 128 | 128 | NDM-1 | – | + | 0.08↓ | 12.44↑ |
| ECL-NX10 | 128 | 128 | 128 | NDM-1 | – | + | 0.20↓ | 8.37↑ |
| ECL-NX11 | 128 | 128 | 128 | NDM-1 | – | + | 0.22↓ | 10.12↑ |
| ECL-NX12 | 128 | 128 | 128 | NDM-1 | – | + | 0.14↓ | 7.62↑ |
| ECL-NX13 | 128 | 128 | 128 | NDM-1 | – | + | 0.15↓ | 9.35↑ |
| ECL-NX14 | 128 | 128 | 128 | NDM-1 | – | + | 0.16↓ | 10.11↑ |
| ECL-NX15 | 128 | 128 | 256 | NDM-1 | – | + | 0.15↓ | 9.91↑ |
| ECL-NX16 | 128 | 128 | 128 | NDM-1 | – | + | 0.22↓ | 11.3↑ |
| ECL-NX17 | 256 | 256 | 256 | NDM-1 | CTX-M; TEM-30 | – | 0.11↓ | 8.41↑ |
| ECL-NX18 | 64 | 8 | 64 | – | CTX-M; TEM-1; SHV-12 | + | 0.06↓ | 0.49↓ |
| ECL-NX19 | 128 | 128 | 128 | IMP-26 | TEM-1; SHV-12 | + | 0.15↓ | 6.92↑ |
| ECL-NX20 | 256 | 256 | 256 | NDM-1 | SHV-12 | + | 0.12↓ | 5.83↑ |
| ECL-NX21 | 128 | 128 | 128 | NDM-1 | – | + | 0.14↓ | 10.05↑ |
| ECL-NX22 | 128 | 128 | 128 | NDM-1 | – | + | 0.14↓ | 9.20↑ |
| ECL-NX23 | 128 | 128 | 128 | NDM-1 | – | + | 0.09↓ | 12.28↑ |
| ECL-NX24 | 32 | 32 | 32 | IMP-4 | SHV-12 | + | 1.58↓ | 13.48↑ |
| ECL-NX25 | 256 | 256 | 256 | NDM-1 | CTX-M; TEM-30 | – | 0.03↓ | 10.59↑ |
| ECL-NX26 | 128 | 128 | 128 | NDM-1 | + | 0.12↓ | 15.44↑ | |
| ECL-NX27 | 32 | 32 | 64 | IMP-4 | CTX-M; SHV-12 | + | 0.06↓ | 6.73↑ |
| ECL-NX28 | 256 | 256 | 256 | NDM-1 | CTX-M; TEM-30 | – | 0.09↓ | 0.01↓ |
| ECL-NX29 | 256 | 256 | 256 | NDM-1 | CTX-M; TEM-30 | – | 0.09↓ | 0.05↓ |
| ECL-NX30 | 128 | 128 | 128 | NDM-1 | – | + | 0.15↓ | 8.98↑ |
| ECL-NX31 | 128 | 128 | 128 | NDM-1 | – | + | 0.19↓ | 6.43↑ |
| ECL-NX32 | 128 | 128 | 128 | NDM-1 | – | + | 0.16↓ | 8.14↑ |
| ECL-NX33 | 128 | 128 | 128 | NDM-1 | – | + | 0.08↓ | 7.85↑ |
| ECL-NX34 | 128 | 128 | 128 | NDM-1 | TEM-30 | + | 0.07↓ | 4.04↑ |
| ECL-NX35 | 256 | 256 | 256 | NDM-1 IMP-1 | TEM-30; SHV-12; LAP-2 | + | 0.01↓ | 6.31↑ |
| ECL-NX36 | 128 | 128 | 128 | NDM-1 | – | + | 0.17↓ | 3.06↑ |
| ECL-NX37 | 128 | 128 | 128 | IMP-26 | TEM-30; SHV-12 | + | 0.16↓ | 3.06↑ |
| ECL-NX38 | 128 | 128 | 128 | NDM-1 | – | + | 0.07↓ | 2.79↑ |
| ECL-NX39 | 64 | 64 | 64 | NDM-1 | CTX-M; TEM-30; SHV-12 | – | 0.23↓ | 5.66↑ |
| ECL-NX40 | 64 | 64 | 64 | NDM-1 | CTX-M; TEM-1; SHV-12 | – | 0.09↓ | 2.81↑ |
| ECL-NX41 | 128 | 128 | 128 | NDM-1 | TEM-1; SHV-12 | + | 0.12↓ | 1.29↑ |
| ECL-SZY01 | 2 | 0.5 | 0.5 | – | – | + | 0.01↓ | 0.01↓ |
| ECL-SZY02 | 2 | 0.5 | 0.5 | – | – | – | 0.01↓ | 0.01↓ |
| ECL-SZY03 | 4 | 0.5 | 0.5 | – | – | + | 0.01↓ | 0.01↓ |
| ECL-SZY04 | 4 | 4 | 4 | – | – | + | 0.01↓ | 0.01↓ |
| ECL-SZY05 | 2 | 0.5 | 0.5 | – | – | + | 0.01↓ | 0.02↓ |
| ECL-SZY06 | 2 | 0.5 | 0.5 | – | – | + | 1.35↑ | 0.01↓ |
| ECL-SZY07 | 2 | 0.5 | 0.5 | – | – | + | 0.06↓ | 0.01↓ |
| ECL-SZY08 | 4 | 1 | 1 | – | – | + | 0.01↓ | 0.01↓ |
| ECL-SZY09 | 2 | 0.5 | 1 | – | – | + | 0.01↓ | 0.01↓ |
| ECL-SZY10 | 2 | 0.5 | 0.5 | – | – | + | 0.01↓ | 0.20↓ |
| ECL-SZY11 | 2 | 0.5 | 0.5 | – | – | + | 0.27↓ | 0.82↓ |
| ECL-SZY12 | 2 | 0.5 | 0.5 | – | – | + | 0.01↓ | 0.01↓ |
| ECL-SZY13 | 1 | 1 | 4 | – | – | – | 0.90↓ | 0.01↓ |
| ECL-SZY14 | 4 | 1 | 1 | – | – | + | 1.20↑ | 0.01↓ |
| ECL-SZY15 | 2 | 2 | 4 | – | – | + | 0.03↓ | 0.01↓ |
| ECL-SZY16 | 4 | 4 | 2 | – | TEM-1 | – | 0.01↓ | 4.5↑ |
| ECL-SZY17 | 2 | 1 | 4 | – | – | – | 0.01↓ | 3.91↑ |
| ECL-SZY18 | 2 | 1 | 4 | – | – | + | 0.01↓ | 0.08↓ |
IPM, imipenem; MEM, meropenem; ETP, ertapenem. Arrows indicated the relative variation of expression in ompC and ompF genes. AmpC β-lactamase was examined by cefoxitin in three-dimensional test. The plus and minus were used to describe the positive or negative results of β-lactamases. Arrows represents up- and down- regulation of OM expression.